ArticleJournal of pharmaceutical sciences2013
Structural characterization of pharmaceutical heparins prepared from different animal tissues.
Article in Journal of pharmaceutical sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 112 citations in OpenAlex.
- Porcine-derived materials in urology Practical ethical guidance for caring for Muslim and Jewish patients.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Review
- The Content and Location of 3-Biomolecules · 2026Article
- Comparison of the Biologic Activity of Different Species of Heparin.Handbook of experimental pharmacology · 2026Review
- Non-anticoagulant heparins: glycan-mediated immune modulation and therapeutic applications.Frontiers in immunology · 2026Review
- Quantitative HILIC-Q-TOF-MS Analysis of Glycosaminoglycans and Non-reducing End Carbohydrate Biomarkers via Glycan Reductive Isotopic Labeling.Analytical chemistry · 2025Article
- Multifaceted role of heparin in oncology: from anticoagulation to anticancer mechanisms and clinical implications.Discover oncology · 2025Review
- Establishment of an in vivo analytical method for detecting total anti-UFH activity and pharmacokinetic study in PS and R15 in rats.PloS one · 2025Article
- Effective removal of host cell-derived nucleic acids bound to hepatitis B core antigen virus-like particles by heparin chromatography.Frontiers in bioengineering and biotechnology · 2024Article
- Non-anticoagulant heparin derivatives for COVID-19 treatment.International journal of biological macromolecules · 2023Review
- Heparin-Induced Changes of Vascular Endothelial Growth Factor (VEGFBiomolecules · 2023Article
- Anticoagulant Activity of Heparins from Different Animal Sources are Driven by a Synergistic Combination of Physical-chemical Factors.TH open : companion journal to thrombosis and haemostasis · 2022Article
- Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate.Pharmaceuticals (Basel, Switzerland) · 2022Article
- A natural heparinoid from molluscCurrent research in food science · 2022Article
- Molecular determinants of the interaction between HSV-1 glycoprotein D and heparan sulfate.Frontiers in molecular biosciences · 2022Article
- Dissecting structure-function of 3-O-sulfated heparin and engineered heparan sulfates.Science advances · 2021Article
- Bioengineered production of glycosaminoglycans and their analogues.Systems microbiology and biomanufacturing · 2021Article
- Advances in the preparation and synthesis of heparin and related products.Drug discovery today · 2020Review
- Specific Non-Reducing Ends in Heparins from Different Animal Origins: Building Blocks Analysis Using Reductive Amination Tagging by Sulfanilic Acid.Molecules (Basel, Switzerland) · 2020Article
- Structural characterization of a clinically described heparin-like substance in plasma causing bleeding.Carbohydrate polymers · 2020Article
- Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.Antiviral research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Although most pharmaceutical heparin used today is obtained from porcine intestine, heparin has historically been prepared from bovine lung and ovine intestine. There is some regulatory concern about establishing the species origin of heparin. This concern began with the outbreak of mad cow disease in the 1990s and was exacerbated during the heparin shortage in the 2000s and the heparin contamination crisis of 2007-2008. Three heparins from porcine, ovine, and bovine were characterized through state-of-the-art carbohydrate analysis methods with a view profiling their physicochemical properties. Differences in molecular weight, monosaccharide and disaccharide composition, oligosaccharide sequence, and antithrombin III-binding affinity were observed. These data provide some insight into the variability of heparins obtained from these three species and suggest some analytical approaches that may be useful in confirming the species origin of a heparin active pharmaceutical ingredient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.